Literature DB >> 33965061

Implementation strategies for passive respiratory syncytial virus immunisation.

Charles J Sande1.   

Abstract

Entities:  

Mesh:

Year:  2021        PMID: 33965061      PMCID: PMC7613528          DOI: 10.1016/S1473-3099(20)30717-9

Source DB:  PubMed          Journal:  Lancet Infect Dis        ISSN: 1473-3099            Impact factor:   71.421


× No keyword cloud information.
  10 in total

1.  Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus.

Authors:  Jason S McLellan; Man Chen; M Gordon Joyce; Mallika Sastry; Guillaume B E Stewart-Jones; Yongping Yang; Baoshan Zhang; Lei Chen; Sanjay Srivatsan; Anqi Zheng; Tongqing Zhou; Kevin W Graepel; Azad Kumar; Syed Moin; Jeffrey C Boyington; Gwo-Yu Chuang; Cinque Soto; Ulrich Baxa; Arjen Q Bakker; Hergen Spits; Tim Beaumont; Zizheng Zheng; Ningshao Xia; Sung-Youl Ko; John-Paul Todd; Srinivas Rao; Barney S Graham; Peter D Kwong
Journal:  Science       Date:  2013-11-01       Impact factor: 47.728

2.  Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group.

Authors: 
Journal:  Pediatrics       Date:  1998-09       Impact factor: 7.124

Review 3.  Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis.

Authors:  Harish Nair; D James Nokes; Bradford D Gessner; Mukesh Dherani; Shabir A Madhi; Rosalyn J Singleton; Katherine L O'Brien; Anna Roca; Peter F Wright; Nigel Bruce; Aruna Chandran; Evropi Theodoratou; Agustinus Sutanto; Endang R Sedyaningsih; Mwanajuma Ngama; Patrick K Munywoki; Cissy Kartasasmita; Eric A F Simões; Igor Rudan; Martin W Weber; Harry Campbell
Journal:  Lancet       Date:  2010-05-01       Impact factor: 79.321

4.  Chimpanzee adenovirus- and MVA-vectored respiratory syncytial virus vaccine is safe and immunogenic in adults.

Authors:  Christopher A Green; Elisa Scarselli; Charles J Sande; Amber J Thompson; Catherine M de Lara; Kathryn S Taylor; Kathryn Haworth; Mariarosaria Del Sorbo; Brian Angus; Loredana Siani; Stefania Di Marco; Cinzia Traboni; Antonella Folgori; Stefano Colloca; Stefania Capone; Alessandra Vitelli; Riccardo Cortese; Paul Klenerman; Alfredo Nicosia; Andrew J Pollard
Journal:  Sci Transl Med       Date:  2015-08-12       Impact factor: 17.956

5.  A novel investigational Fc-modified humanized monoclonal antibody, motavizumab-YTE, has an extended half-life in healthy adults.

Authors:  Gabriel J Robbie; Ryan Criste; William F Dall'acqua; Kathryn Jensen; Nita K Patel; Genevieve A Losonsky; M Pamela Griffin
Journal:  Antimicrob Agents Chemother       Date:  2013-09-30       Impact factor: 5.191

6.  Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants.

Authors:  M Pamela Griffin; Yuan Yuan; Therese Takas; Joseph B Domachowske; Shabir A Madhi; Paolo Manzoni; Eric A F Simões; Mark T Esser; Anis A Khan; Filip Dubovsky; Tonya Villafana; John P DeVincenzo
Journal:  N Engl J Med       Date:  2020-07-30       Impact factor: 176.079

Review 7.  Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study.

Authors:  Ting Shi; David A McAllister; Katherine L O'Brien; Eric A F Simoes; Shabir A Madhi; Bradford D Gessner; Fernando P Polack; Evelyn Balsells; Sozinho Acacio; Claudia Aguayo; Issifou Alassani; Asad Ali; Martin Antonio; Shally Awasthi; Juliet O Awori; Eduardo Azziz-Baumgartner; Henry C Baggett; Vicky L Baillie; Angel Balmaseda; Alfredo Barahona; Sudha Basnet; Quique Bassat; Wilma Basualdo; Godfrey Bigogo; Louis Bont; Robert F Breiman; W Abdullah Brooks; Shobha Broor; Nigel Bruce; Dana Bruden; Philippe Buchy; Stuart Campbell; Phyllis Carosone-Link; Mandeep Chadha; James Chipeta; Monidarin Chou; Wilfrido Clara; Cheryl Cohen; Elizabeth de Cuellar; Duc-Anh Dang; Budragchaagiin Dash-Yandag; Maria Deloria-Knoll; Mukesh Dherani; Tekchheng Eap; Bernard E Ebruke; Marcela Echavarria; Carla Cecília de Freitas Lázaro Emediato; Rodrigo A Fasce; Daniel R Feikin; Luzhao Feng; Angela Gentile; Aubree Gordon; Doli Goswami; Sophie Goyet; Michelle Groome; Natasha Halasa; Siddhivinayak Hirve; Nusrat Homaira; Stephen R C Howie; Jorge Jara; Imane Jroundi; Cissy B Kartasasmita; Najwa Khuri-Bulos; Karen L Kotloff; Anand Krishnan; Romina Libster; Olga Lopez; Marilla G Lucero; Florencia Lucion; Socorro P Lupisan; Debora N Marcone; John P McCracken; Mario Mejia; Jennifer C Moisi; Joel M Montgomery; David P Moore; Cinta Moraleda; Jocelyn Moyes; Patrick Munywoki; Kuswandewi Mutyara; Mark P Nicol; D James Nokes; Pagbajabyn Nymadawa; Maria Tereza da Costa Oliveira; Histoshi Oshitani; Nitin Pandey; Gláucia Paranhos-Baccalà; Lia N Phillips; Valentina Sanchez Picot; Mustafizur Rahman; Mala Rakoto-Andrianarivelo; Zeba A Rasmussen; Barbara A Rath; Annick Robinson; Candice Romero; Graciela Russomando; Vahid Salimi; Pongpun Sawatwong; Nienke Scheltema; Brunhilde Schweiger; J Anthony G Scott; Phil Seidenberg; Kunling Shen; Rosalyn Singleton; Viviana Sotomayor; Tor A Strand; Agustinus Sutanto; Mariam Sylla; Milagritos D Tapia; Somsak Thamthitiwat; Elizabeth D Thomas; Rafal Tokarz; Claudia Turner; Marietjie Venter; Sunthareeya Waicharoen; Jianwei Wang; Wanitda Watthanaworawit; Lay-Myint Yoshida; Hongjie Yu; Heather J Zar; Harry Campbell; Harish Nair
Journal:  Lancet       Date:  2017-07-07       Impact factor: 79.321

8.  Respiratory Syncytial Virus Vaccination during Pregnancy and Effects in Infants.

Authors:  Shabir A Madhi; Fernando P Polack; Pedro A Piedra; Flor M Munoz; Adrian A Trenholme; Eric A F Simões; Geeta K Swamy; Sapeckshita Agrawal; Khatija Ahmed; Allison August; Abdullah H Baqui; Anna Calvert; Janice Chen; Iksung Cho; Mark F Cotton; Clare L Cutland; Janet A Englund; Amy Fix; Bernard Gonik; Laura Hammitt; Paul T Heath; Joanne N de Jesus; Christine E Jones; Asma Khalil; David W Kimberlin; Romina Libster; Conrado J Llapur; Marilla Lucero; Gonzalo Pérez Marc; Helen S Marshall; Masebole S Masenya; Federico Martinón-Torres; Jennifer K Meece; Terry M Nolan; Ayman Osman; Kirsten P Perrett; Joyce S Plested; Peter C Richmond; Matthew D Snape; Julie H Shakib; Vivek Shinde; Tanya Stoney; D Nigel Thomas; Alan T Tita; Michael W Varner; Manu Vatish; Keith Vrbicky; Judy Wen; Khalequ Zaman; Heather J Zar; Gregory M Glenn; Louis F Fries
Journal:  N Engl J Med       Date:  2020-07-30       Impact factor: 91.245

9.  Respiratory syncytial virus seasonality and prevention strategy planning for passive immunisation of infants in low-income and middle-income countries: a modelling study.

Authors:  You Li; David Hodgson; Xin Wang; Katherine E Atkins; Daniel R Feikin; Harish Nair
Journal:  Lancet Infect Dis       Date:  2021-05-06       Impact factor: 25.071

Review 10.  Priorities for developing respiratory syncytial virus vaccines in different target populations.

Authors:  Simon B Drysdale; Rachael S Barr; Christine S Rollier; Christopher A Green; Andrew J Pollard; Charles J Sande
Journal:  Sci Transl Med       Date:  2020-03-18       Impact factor: 19.319

  10 in total
  1 in total

Review 1.  RSV Prevention in All Infants: Which Is the Most Preferable Strategy?

Authors:  Susanna Esposito; Bahaa Abu Raya; Eugenio Baraldi; Katie Flanagan; Federico Martinon Torres; Maria Tsolia; Stefan Zielen
Journal:  Front Immunol       Date:  2022-04-28       Impact factor: 8.786

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.